Investigation of the aerotropolis concept and its transferability around the world

Academic and industrial literature highlight the importance of airport-driven development (ADD) for the 21st Century. Several different types of ADD concepts have been defined, such as aerotropolis and airport city, but there are often substantial differences between authors about definitions. Such differences can potentially create confusion when ADD concepts are used by airport planners in their planning documents (e.g., master plans) and the marketing materials (e.g., brochures and airport websites). Given that large amounts of investment can often depend upon the marketing of a particular ADD concept, such confusion is highly problematic for the air transport industry. However, previous research has not explicitly addressed this issue. To help fill this research gap, the current paper has four different purposes, to: (1) compare definitions of the airport-driven development concepts in the academic literature, (2) compare definitions with real-life examples given by researchers; (3) compare academic definitions and examples with industry usage, as found on airport websites and in airport planning documents; and (4) investigate aspects of the transferability of the ADD concepts (from one region to another and from the academic literature to the industry and vice-versa). Using information from airport websites and master plans, it was found that the terms aerotropolis and airport city are used interchangeably by researchers but not by the industry. However, the use of terms by the industry depends heavily upon the (continental) location of airports, with the analysis presented in the paper distinguishing between airports in North America, Latin America, South and East Asia, Europe and the Middle East. Such analysis enables conclusions to be made about the transferability of ADD concepts, originating in the Global North, to the Global South

Healthy lifestyle is associated with reduced cardiovascular disease, depression and mortality in people at elevated risk of sleep apnea

OnlinePublWe assessed: (1) the independent and joint association of obstructive sleep apnea risk and healthy lifestyle with common consequences (excessive daytime sleepiness, depression, cardiovascular disease and stroke) of obstructive sleep apnea; and (2) the effect of healthy lifestyle on survival in people with increased obstructive sleep apnea risk. Data from 13,694 adults (median age 46 years; 50% men) were used for cross-sectional and survival analyses (mortality over 15 years). A healthy lifestyle score with values from 0 (most unhealthy) to 5 (most healthy) was determined based on diet, alcohol intake, physical activity, smoking and body mass index. In the crosssectional analysis, obstructive sleep apnea risk was positively associated with all chronic conditions and excessive daytime sleepiness in a dose–response manner (p for trend < 0.001). The healthy lifestyle was inversely associated with all chronic conditions (p for trend < 0.001) but not with excessive daytime sleepiness (p for trend = 0.379). Higher healthy lifestyle score was also associated with reduced odds of depression and cardiovascular disease. We found an inverse relationship between healthy lifestyle score with depression (p for trend < 0.001), cardiovascular disease (p for trend = 0.003) and stroke (p for trend = 0.025) among those who had high obstructive sleep apnea risk. In the survival analysis, we found an inverse association between healthy lifestyle and all-cause mortality for all categories of obstructive sleep apnea risk (moderate/high- and high-risk groups [p for trend < 0.001]). This study emphasises the crucial role of a healthy lifestyle in mitigating the effects of obstructive sleep apnea risk in individuals with an elevated obstructive sleep apnea risk.Yohannes Adama Melaku, Sarah Appleton, Amy C. Reynolds, Roger L. Milne, Brigid M. Lynch, Danny J. Eckert, Robert Adam

Islands of linkage in an ocean of pervasive recombination reveals two-speed evolution of human cytomegalovirus genomes

Human cytomegalovirus (HCMV) infects most of the population worldwide, persisting throughout the host's life in a latent state with periodic episodes of reactivation. While typically asymptomatic, HCMV can cause fatal disease among congenitally infected infants and immunocompromised patients. These clinical issues are compounded by the emergence of antiviral resistance and the absence of an effective vaccine, the development of which is likely complicated by the numerous immune evasins encoded by HCMV to counter the host's adaptive immune responses, a feature that facilitates frequent super-infections. Understanding the evolutionary dynamics of HCMV is essential for the development of effective new drugs and vaccines. By comparing viral genomes from uncultivated or low-passaged clinical samples of diverse origins, we observe evidence of frequent homologous recombination events, both recent and ancient, and no structure of HCMV genetic diversity at the whole-genome scale. Analysis of individual gene-scale loci reveals a striking dichotomy: while most of the genome is highly conserved, recombines essentially freely and has evolved under purifying selection, 21 genes display extreme diversity, structured into distinct genotypes that do not recombine with each other. Most of these hyper-variable genes encode glycoproteins involved in cell entry or escape of host immunity. Evidence that half of them have diverged through episodes of intense positive selection suggests that rapid evolution of hyper-variable loci is likely driven by interactions with host immunity. It appears that this process is enabled by recombination unlinking hyper-variable loci from strongly constrained neighboring sites. It is conceivable that viral mechanisms facilitating super-infection have evolved to promote recombination between diverged genotypes, allowing the virus to continuously diversify at key loci to escape immune detection, while maintaining a genome optimally adapted to its asymptomatic infectious lifecycle

Environmental monitoring : phase 5 final report (April 2019 - March 2020)

This report presents the results and interpretation for Phase 5 of an integrated environmental monitoring programme that is being undertaken around two proposed shale gas sites in England – Preston New Road, Lancashire and Kirby Misperton, North Yorkshire. The report should be read in conjunction with previous reports freely available through the project website1 . These provide additional background to the project, presentation of earlier results and the rationale for establishment of the different elements of the monitoring programme

Environmental monitoring : phase 4 final report (April 2018 - March 2019)

This report describes the results of activities carried out as part of the Environmental Monitoring Project (EMP) led by the British Geological Survey (BGS) in areas around two shale gas sites in England – Kirby Misperton (Vale of Pickering, North Yorkshire) and Preston New Road (Fylde, Lancashire). It focuses on the monitoring undertaken during the period April 2018–March 2019 but also considers this in the context of earlier monitoring results that have been covered in reports for earlier phases of the project (Phases I–IV) 2 . The EMP project is a multi-partner project involving BGS together with Public Health England (PHE), University of Birmingham, University of Bristol, University of Manchester, Royal Holloway University of London (RHUL) and University of York. The work has been enabled by funding from a combination of the BGS National Capability programme, a grant awarded by the UK Government’s Department for Business Energy & Industrial Strategy (BEIS) and additional benefit-in-kind contributions from all partners. The project comprises the comprehensive monitoring of different environment compartments and properties at and around the two shale-gas sites. The component parts of the EMP are all of significance when considering environmental and human health risks associated with shale gas development. Included are seismicity, ground motion, water (groundwater and surface water), soil gas, greenhouse gases, air quality, and radon. The monitoring started before hydraulic fracturing had taken place at the two locations, and so the results obtained before the initiation of operations at the shale-gas sites represent baseline conditions. It is important to characterise adequately the baseline conditions so that any future changes caused by shale gas operations, including hydraulic fracturing, can be identified. This is also the case for any other new activities that may impact those compartments of the environment being monitored as part of the project. In the period October 2018–December 2018, an initial phase of hydraulic fracturing took place at the Preston New Road (PNR) shale-gas site (shale gas well PNR1-z) in Lancashire. This was followed by a period of flow testing of the well to assess its performance (to end of January 2019). The project team continued monitoring during these various activities and several environmental effects were observed. These are summarised below and described in more detail within the report. The initiation of operations at the shale-gas site signified the end of baseline monitoring. At the Kirby Misperton site (KMA), approval has not yet been granted for hydraulic fracturing of the shale gas well (KM8), and so no associated operations have taken place during the period covered by this report. The effects on air quality arising from the mobilisation of equipment in anticipation of hydraulic fracturing operations starting was reported in the Phase III report, and in a recently published paper3 . Following demobilisation of the equipment and its removal from the site, conditions returned to baseline and the on-going monitoring (reported in this report) is effectively a continuation of baseline monitoring

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers

Purpose To determine whether adjuvant tamoxifen treatment for breast cancer (BC) is associated with reduced contralateral breast cancer (CBC) risk for BRCA1 and/or BRCA2 mutation carriers. Methods Analysis of pooled observational cohort data, self-reported at enrollment and at follow-up from the International BRCA1, and BRCA2 Carrier Cohort Study, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, and Breast Cancer Family Registry. Eligible women were BRCA1 and BRCA2 mutation carriers diagnosed with unilateral BC since 1970 and no other invasive cancer or tamoxifen use before first BC. Hazard ratios (HRs) for CBC associated with tamoxifen use were estimated using Cox regression, adjusting for year and age of diagnosis, country, and bilateral oophorectomy and censoring at contralateral mastectomy, death, or loss to follow-up. Results Of 1,583 BRCA1 and 881 BRCA2 mutation carriers, 383 (24%) and 454 (52%), respectively, took tamoxifen after first BC d

The BRCA2 c.68-7T > A variant is not pathogenic : A model for clinical calibration of spliceogenicity

Although the spliceogenic nature of the BRCA2 c.68-7T > A variant has been demonstrated, its association with cancer risk remains controversial. In this study, we accurately quantified by real-time PCR and digital PCR (dPCR), the BRCA2 isoforms retaining or missing exon 3. In addition, the combined odds ratio for causality of the variant was estimated using genetic and clinical data, and its associated cancer risk was estimated by case-control analysis in 83,636 individuals. Co-occurrence in trans with pathogenic BRCA2 variants was assessed in 5,382 families. Exon 3 exclusion rate was 4.5-fold higher in variant carriers (13%) than controls (3%), indicating an exclusion rate for the c.68-7T > A allele of approximately 20%. The posterior probability of pathogenicity was 7.44x10(-115). There was neither evidence for increased risk of breast cancer (OR 1.03; 95% CI 0.86-1.24) nor for a deleterious effect of the variant when co-occurring with pathogenic variants. Our data provide for the first time robust evidence of the nonpathogenicity of the BRCA2 c.68-7T > A. Genetic and quantitative transcript analyses together inform the threshold for the ratio between functional and altered BRCA2 isoforms compatible with normal cell function. These findings might be exploited to assess the relevance for cancer risk of other BRCA2 spliceogenic variants.Peer reviewe

Classification of Supernovae

The current classification scheme for supernovae is presented. The main observational features of the supernova types are described and the physical implications briefly addressed. Differences between the homogeneous thermonuclear type Ia and similarities among the heterogeneous core collapse type Ib, Ic and II are highlighted. Transforming type IIb, narrow line type IIn, supernovae associated with GRBs and few peculiar objects are also discussed.Comment: 16 Pages, 4 figures, to be published in "Supernovae and Gamma-Ray Bursters," ed. Kurt W. Weile

Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus.

BACKGROUND: Multiple recent genome-wide association studies (GWAS) have identified a single nucleotide polymorphism (SNP), rs10771399, at 12p11 that is associated with breast cancer risk. METHOD: We performed a fine-scale mapping study of a 700 kb region including 441 genotyped and more than 1300 imputed genetic variants in 48,155 cases and 43,612 controls of European descent, 6269 cases and 6624 controls of East Asian descent and 1116 cases and 932 controls of African descent in the Breast Cancer Association Consortium (BCAC; http://bcac.ccge.medschl.cam.ac.uk/ ), and in 15,252 BRCA1 mutation carriers in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Stepwise regression analyses were performed to identify independent association signals. Data from the Encyclopedia of DNA Elements project (ENCODE) and the Cancer Genome Atlas (TCGA) were used for functional annotation. RESULTS: Analysis of data from European descendants found evidence for four independent association signals at 12p11, represented by rs7297051 (odds ratio (OR) = 1.09, 95 % confidence interval (CI) = 1.06-1.12; P = 3 × 10(-9)), rs805510 (OR = 1.08, 95 % CI = 1.04-1.12, P = 2 × 10(-5)), and rs1871152 (OR = 1.04, 95 % CI = 1.02-1.06; P = 2 × 10(-4)) identified in the general populations, and rs113824616 (P = 7 × 10(-5)) identified in the meta-analysis of BCAC ER-negative cases and BRCA1 mutation carriers. SNPs rs7297051, rs805510 and rs113824616 were also associated with breast cancer risk at P < 0.05 in East Asians, but none of the associations were statistically significant in African descendants. Multiple candidate functional variants are located in putative enhancer sequences. Chromatin interaction data suggested that PTHLH was the likely target gene of these enhancers. Of the six variants with the strongest evidence of potential functionality, rs11049453 was statistically significantly associated with the expression of PTHLH and its nearby gene CCDC91 at P < 0.05. CONCLUSION: This study identified four independent association signals at 12p11 and revealed potentially functional variants, providing additional insights into the underlying biological mechanism(s) for the association observed between variants at 12p11 and breast cancer risk.UK funding includes Cancer Research UK and NIH.This is the final version of the article. It first appeared from BioMed Central via http://dx.doi.org/10.1186/s13058-016-0718-